Clarus Builds Investment Team

Feb 10 2006 | 10:18pm ET

Clarus Ventures, a global life sciences venture capital firm with offices in San Francisco and Cambridge, Mass., has filled out its investment team to manage its first fund, which closed in December with $500 million in committed capital. The firm has hired three principals and a controller to help manage the fund and Robert Liptak, managing director, said the firm is looking to make one additional hire.

The newly-formed team includes Emmett Cunningham, Michele Park and Scott Requadt, who have joined the firm as principals, and Danielle Bechard, who has joined as controller.

Prior to joining the firm's San Francisco office, Cunningham was senior vice president of medical strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development and approval of Macugen, a drug used to help age-related macular degeneration.

Park joins the San Francisco office of Clarus from Credit Suisse First Boston, where she was an analyst covering large, medium and small capitalization biotechnology companies with a focus on companies with oncologic and anti-infective products.

Requadt joins the Cambridge office from TransForm Pharmaceuticals, where he was director of business development.

Finally, Bechard joins the Cambridge office from the McDonald's Corporation, where she was responsible for franchisee analysis.

The fund will invest in predominantly later-stage biotechnology firms, Liptak said.


In Depth

Q&A: Reg A+ Will Transform the Alternative Asset Landscape

Jul 7 2015 | 4:03pm ET

In addition to easing capital formation for small companies, Regulation A+ has enormous...

Lifestyle

Fiat Chrysler Files Paperwork For Ferrari IPO

Jul 23 2015 | 5:05pm ET

Italian sportscar maker Ferrari has taken a step closer to a stock market listing...

Guest Contributor

Lifting of Foreign Ownership Limits Signals Sea Change in Vietnam's Capital Markets

Jul 28 2015 | 3:01pm ET

The lifting of restrictions on foreign ownership limits in Vietnam later this year...

 

Editor's Note